Clinical Trial Update: Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas [Phase 2]

View source ↗

Summary

Phase 2 randomized trial comparing gemcitabine plus nab-paclitaxel versus S-1 plus nab-paclitaxel in metastatic pancreatic adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Pancreatic Cancer, Nab-paclitaxel | Phase 2 | Status: UNKNOWN